Heart failure & cardiomyopathies
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial
Authors' conclusion
Patients with oHCM and mild symptoms treated with aficamten achieved significant improvement across a range of clinically relevant outcomes and generally similar to patients with more advanced symptoms.
Study context
- Population
- Patients with obstructive hypertrophic cardiomyopathy (oHCM) in SEQUOIA-HCM
- Participants
- 282 patients
- Comparison
- Aficamten in mild vs moderate to severe symptoms
- Mild symptomsn = 118
- Moderate to severe symptomsn = 150reference
- Primary endpoint
- Change in peak oxygen uptake (pVO2) from baseline
- Follow-up
- Week 24
Methodological detailssubgroup analysis by baseline symptom severity
- Subgroup analysis by baseline symptom severity
Primary result
As reported in the abstract
Change in pVO2, aficamten-treated
Moderate to severe symptoms
1.8
mL/kg/min · n = 71
Mild symptoms
1.6
mL/kg/min · n = 62
P = 0.8
Secondary outcomes
New York Heart Association (NYHA) class, resting or Valsalva gradients, NT-proBNP
- Change did not differ significantly between the two symptom groups
Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
- Significant improvement in both groups; greater in the advanced symptom group
- P = 0.02 for interaction
- Interaction P = .02
Safety
Treatment-emergent serious adverse events
- Infrequent in both groups
Original publication
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. Published 17 May 2025. doi:10.
Summarised from the published abstract; every number is checked against it